Ruiai Chen

Dr. Ruiai Chen received her Ph.D. in Microbiology from the China Agricultural University. Currently she is a professor and Ph.D. advisor at the College of Veterinary Medicines, South China Agricultural University.

Dr. Chen is President of Guangdong Wens Dahuanong Biotechnology Co., Ltd. (DHN), and Vice-Chairman of the China Veterinary Drug Association (CVDA). She is one of the most influential leaders in the Chinese animal health arena and, as a result, she is entitled to special allowances provided by the Chinese State Council, an honor for outstanding scientists in China. Dr. Chen is a well-known expert in the prevention and control of animal diseases, and vaccine research.

She possesses 41 patents and 22 new veterinary drug certificates. Dr. Chen has received 14 technical awards at the provincial and national levels, such as first prize for the Guangdong Provincial Science and Technology Award and the China Outstanding Patent. Her achievements include the development and industrialization of avian influenza vaccines, PRRS vaccines and coccidiosis vaccines. These vaccines are now making great contributions to disease control in China, Southeast Asia (e.g., Indonesia), and Middle East countries. Dr. Chen is also director of the Enterprise Key Laboratory of MOA for Animal Disease Prevention and Control, Biotechnology and Biological Product R&D. She has contributed greatly to commercialization of technology for animal vaccine and pharmaceutical products.

Norman Lee

Norman Lee, Ph.D., Professor and founder of Tianjin Ringpu Bio-Technology Co. Ltd., Director of the MOA’s Key Laboratory for Veterinary Drug Innovation, Chairman of the National Veterinary Drug Industry Strategic Alliance for Technology and Innovation, Vice-President of the Chinese Veterinary Association, President of the Tianjin Veterinary Medicine Association, post-graduate advisor at the Tianjin Agricultural University. Dr. Lee has led over 21 national, provincial, and municipal science and technology projects. He was recipient of the second prize of the National Science and Technology Progress Award and twice of the first prize of the Tianjin Science and Technology Progress Award.

In 1998, Dr. Lee established Ringpu(Tianjin)Bio-Pharmacy Co. Ltd. And Ringpu (Baoding) Biological Pharmaceutical Co., Ltd. He also acted as General Manager of both companies.

In 2004, he was in charge of the research project: “Genetically engineering recombinant chicken α- interferon”. The project received the first prize of the Tianjin City Technology Innovation Award.

In 2008, he led a management team to restructure the company and established Tianjin Ringpu Bio-Technology Co. Ltd. He was appointed Acting Chairman of the Board.

On 17th September 2010, Tianjin Ringpu Bio-Technology Co. Ltd. was officially listed on the Shenzhen Stock Exchange and Dr. Lee is Chairman of the Board,

In 2012, Dr. Lee was part of the research team: “Swine and poultry pathogenic bacteria resistance research and its application in development of a safe and effective new veterinary drug”. The project received the second prize of the National Science and Technology Progress Award.

Mr Sun Jinzhong

Mr.Sun Jinzhong was born in 1965, graduated from China agricultural university, major in veterinary , master degree, senior veterinary .He is vice chairman of  PULIKE biological engineering co., LTD.,  Deputy Director of the National Research Center for Veterinary Medicine,  Luoyang standing committee member , Vice President of China animal husbandry and veterinary institute – biological products branch,  Deputy secretary-general of poultry epidemiology branch of China animal husbandry and veterinary institute council, China veterinary drug standard committee member, Vice chairman of Henan animal health products

association,  Luoyang biological engineering expert technical committee member, Director and deputy secretary general the eighth session of board of Henan animal husbandry and veterinary institute, etc.

Mr Sun Jinzhong hosted and participated in various of science and technology projects, was awarded more than ten technology progress prizes as National, Henan province, Luoyang.Successively .He has won the qualifications and honorary titles as following:”Outstanding contribution high-level talent award of Luoyang high and new technology zone”, “Outstanding entrepreneurs of Luoyang high and new technology zone “, “the seventh batch of Luoyang excellent experts”, “Excellent leaguer of China Democratic League luoyang committee”, “Luoyang May 1 labor medal”, ” The third Luoyang excellent top 100 private science and technology industrialist  “, “Advanced individual of promote agriculture by scientific technology in Henan province”, “Henan province government special allowance experts”.

孙进忠，1965年出生，毕业于中国农业大学兽医专业，硕士研究生学历，高级兽医师。现担任普莱柯生物工程股份有限公司副董事长职务，目前还担任国家兽用药品工程技术研究中心副主任、洛阳市政协常委、中国畜牧兽医学会生物制品学分会副理事长、中国畜牧兽医学会禽病学分会理事会理事兼任副秘书长、中国兽药典委员会委员、河南省动物保健品协会副会长、洛阳市生物工程专家技术委员会委员、河南省畜牧兽医学会第八届理事会理事、副秘书长等职务。

孙进忠先生主持、参与国家、省市各类科技项目多项，获国家、河南省、洛阳市科技进步奖10余项。先后荣获“洛阳市高新区突出贡献高层次人才奖”、“洛阳市高新区优秀企业家”、“第七批洛阳市优秀专家”、“民盟洛阳市委员会优秀盟员”、“洛阳市五一劳动奖章”、“洛阳市第三届优秀百佳民营科技实业家”、“河南省科技兴农先进个人”、“河南省政府特殊津贴专家”等资质、荣誉称号。

Yongsheng Wang

Dr. Zhao Yarong

Professor, Yarong ZHAO received Ph.D. in Veterinary Parasitology from China Agricultural University in 1993. With his cutting-edge researches in cryptosporidiosis, he received the First Grade Science & Technology Award from the Chinese Ministry of Agriculture in 1993.

From 1993 to 1998, he worked as National Technical Manager in Bayer Animal Health China. Later then in Fort Dodge Animal Health and Schering-Plough China as Regulatory and Technical Manager.

In 2003, he was appointed as General Manager of the Animal Medicine Research Center of the Dabeinong (DBN) Group, an innovative R&D center which focusing on animal infection disease diagnosis, animal biologic development and technology transfer. He has published over 50 scientific papers. Under his leadership, the Center has obtained Six National New Veterinary Drug Certificates and complete a number of technology transfer to other animal health companies with a total transaction value of approximately 350 million(RMB); Inactivated porcine circovirus type 2 (PCV2) vaccines, won the First Class State Science & Technology Progress Award in 2012.

Dr. Tingwu Xue

Dr. XUE Tingwu is the President of China Animal Husbandry Group. He has been working for the company for over 30 years, with tremendous experience and knowledge in China’s agriculture industry, China’s animal husbandry industry, China’s animal health industry. He also is the pioneer who is dedicated to promote companies which serve safety agro-products and animal-related products to Chinese publics.

He is also actively engaged in various industry-related associations to fulfill his duty to the society. He is the key leading member of China Animal Agriculture Association, and vice-president of China Veterinary Drug Association, etc..

Plus, He is the founder and chairman of China Animal Health International Forum, which has been a platform to share information among animal health companies in order to promote the sustainable development of China animal health industry.

Joachim Hasenmaier

Joachim Hasenmaier, born 1960 in Vaihingen/Enz, Germany, DVM., is Member of the Board of Managing Directors of C.H. Boehringer Sohn AG & Co. KG since October 1, 2012, responsible for the Corporate Board Division Consumer Health Care and Animal Health. His nationality is German.

He received a veterinary medical degree (DVM) in 1986 from Ludwig-Maximilians-University, Munich, where he entered into a microbiological research program until 1989 receiving his Doktor med. vet. (PhD) degree. He completed his education with a Master in Management from Kellogg Business School, Chicago, USA in 1991. Prior to joining BI he worked in various positions for various international companies in Germany, Japan, Mexico and Brazil.

In 2002 he joined Boehringer Ingeheim as Corporate Senior Vice President for Boehringer Ingelheim Animal Health. In 2011 he took over the regional responsibilty for Prescription Medicine in NECAR (UK/Ireland, Nordics, Benelux, Canada, Australia/New Zealand). He held this position until he became Member of the Board of Managing Directors at C.H. Boehringer Sohn AG & Co. KG in October 2012.

Dirk Ehle

Dr. Dirk Ehle has been a member of the Bayer HealthCare Executive Committee and responsible for the Animal Health Division since May 1, 2012.

Dirk Ehle was born on May 26, 1969, in Cologne, Germany. He studied law at the universities of Freiburg, Aix-en-Provence (France), Wurzburg, and New York (USA).

After three years in law firms, Dirk Ehle started his career at Bayer in 2001 in the Law Department of Bayer HealthCare. In 2006, Ehle transferred to Bayer AG’s Corporate Office where he worked as Executive Assistant to the Chairman of the Board of Management. He was also in charge of Corporate Policy & Advocacy as of 2008. In 2010, Ehle was appointed Senior Bayer Representative for Central Eastern Europe and Bayer HealthCare Representative for Poland.

Dirk Ehle is married with three children.

Wim Stocks

Todd Harris

Todd Harris (@ToddAlanHarris) – Todd is Chief Operating Officer of Hi-Rez Studios, one of the largest video game studios in the Southeast United States and a leading developer of competitive online games.  Todd began his career as a software engineer at NCR before taking on product development leadership roles at Radiant Systems and BlueCube Software. In 2005, he left FinTech for the games industry when he co-founded Hi-Rez Studios.  Hi-Rez’ most popular title is the mythology themed, action game SMITE which has over 25 million players on the PC and is a top free-to-play game on the Xbox One and Playstation 4.  In 2016 more than $3,000,000 in cash prizing was awarded to the best Smite players and the January 2017 World Championship in Atlanta was viewed online by over 5 million people.   Todd and Hi-Rez Studios are now developing the fantasy team-based shooter Paladins and the turn-based strategy game Smite Tactics.